Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
21/10/2026 13:32
BRIEF-Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026 Oct 21 (Reuters) - Achieve Life Sciences, Inc. ACHV.O:
ACHIEVE LIFE SCIENCES PRESENTS 52-WEEK CYTISINICLINE RESULTS FOR SMOKING AND VAPING CESSATION AT CHEST 2026
Source text: ID:nGNX203bQR
Further company coverage: ACHV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock